Financial Incentives and Weight Loss in Failed Bariatric Surgery

NCT ID: NCT06910735

Last Updated: 2025-04-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

264 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-30

Study Completion Date

2029-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This national, prospective, multicenter, and randomized study seeks to evaluate the effect of financial incentives on weight loss in individuals who experience weight regain following bariatric surgery. The study also aims to conduct a cost-utility analysis to measure the effectiveness of the intervention and assess the potential budgetary implications if it were to be implemented on a wider scale.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Our intervention is based on the principle of "contingency management" whereby financial rewards are contingent upon meeting specific weight loss targets. To assess the effectiveness of this approach, patients who have experienced weight regain after bariatric surgery will be randomly assigned to one of three groups. Group 1 will receive the standard care that includes setting a weight-loss target based on the weight achieved at 12 months post-bariatric surgery following the standard multidisciplinary follow-up at the inclusion center. Group 2 will receive the same treatment as the control group (Group 1), but with an additional financial incentive if the weight loss target (corresponding to the weight they reached 12 months after bariatric surgery) is achieved 12 months after inclusion. Group 3 will receive the same treatment as the control group (Group 1), but the financial incentive will be proportional to the actual weight loss achieved relative to the weight loss target (corresponding to the weight they reached 12 months after bariatric surgery).

The study will include a standard post-bariatric surgery follow-up visits scheduled at 6, 12, 18, and 24 months, as per routine practice. At the 12-month visit, participants will be eligible to receive a financial incentive based on their arm assignment and the extent of weight loss achieved. After the 12-month visit, participants will not receive any additional financial incentives until the 24-month visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Obesity Recidivism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Group Type OTHER

Control

Intervention Type OTHER

Participants will receive the standard care that includes setting a weight-loss target based on the weight achieved at 12 months post-bariatric surgery following the standard multidisciplinary follow-up at the inclusion center

Threshold financial incentive

Group Type EXPERIMENTAL

Threshold financial incentive

Intervention Type BEHAVIORAL

Participants will receive the standard care with an additional financial incentive of 300 € if they successfully achieve the weight loss target corresponding to their weight at 12 months after bariatric surgery. This financial incentive will be awarded 12 months after their inclusion in the study.

Proportional financial incentive

Group Type EXPERIMENTAL

Proportional financial incentive

Intervention Type BEHAVIORAL

Participants will receive the standard care with an additional financial incentive, which will be determined based on the proportion of their actual weight loss in relation to the predefined weight loss target corresponding to their weight at 12 months after bariatric surgery. The financial incentive can be up to 300 € if the weight loss target is achieved 12 months after their inclusion in the study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Control

Participants will receive the standard care that includes setting a weight-loss target based on the weight achieved at 12 months post-bariatric surgery following the standard multidisciplinary follow-up at the inclusion center

Intervention Type OTHER

Threshold financial incentive

Participants will receive the standard care with an additional financial incentive of 300 € if they successfully achieve the weight loss target corresponding to their weight at 12 months after bariatric surgery. This financial incentive will be awarded 12 months after their inclusion in the study.

Intervention Type BEHAVIORAL

Proportional financial incentive

Participants will receive the standard care with an additional financial incentive, which will be determined based on the proportion of their actual weight loss in relation to the predefined weight loss target corresponding to their weight at 12 months after bariatric surgery. The financial incentive can be up to 300 € if the weight loss target is achieved 12 months after their inclusion in the study.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female over 18 years of age
* Patients with a history of adjustable gastric banding, sleeve gastrectomy, gastric bypass or SADI-sleeve surgery
* Patient with a post-operative delay of more than 2 years
* Patient who has gained ≥10% of the maximum weight lost
* Patient still obese (body mass index ≥ 30 kg/m²) after surgery

Exclusion Criteria

* Pregnant women
* Women of childbearing potential planning a pregnancy during the first year of the study
* Persons under legal protection (safeguard of justice, guardianship, curatorship, etc.)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ministry of Health, France

OTHER_GOV

Sponsor Role collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sébastien Czernichow, MD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AP-HP - hôpital Avicenne

Bobigny, , France

Site Status

AP-HP - hôpital Louis-Mourier

Colombes, , France

Site Status

Centre hospitalier intercommunal de Créteil

Créteil, , France

Site Status

AP-HM - hôpital de la Conception

Marseille, , France

Site Status

CHU de Nantes - hôpital Laënnec

Nantes, , France

Site Status

CHR d'Orléans - hôpital La Source

Orléans, , France

Site Status

AP-HP - hôpital de la Pitié-Salpêtrière

Paris, , France

Site Status

AP-HP - hôpital européen Georges-Pompidou

Paris, , France

Site Status

AP-HP - hôpital Bichat - Claude-Bernard

Paris, , France

Site Status

CHU de Poitiers

Poitiers, , France

Site Status

CHU de Reims - hôpital Robert-Debré

Reims, , France

Site Status

CHU de Nancy - hôpital Brabois

Vandœuvre-lès-Nancy, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Coralie Villeret

Role: CONTACT

+33 1 40 27 52 66

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sopio TATULASHVILI, MD

Role: primary

Séverine LEDOUX, MD

Role: primary

Sarah BATHAEI, MD

Role: primary

Bénédicte GABORIT, MD

Role: primary

David JACOBI, MD

Role: primary

Adel ABOU-MRAD, MD

Role: primary

Judith ARON WISNEWSKY, MD

Role: primary

Sébastien CZERNICHOW, MD

Role: primary

Tigran POGHOSYAN, MD

Role: primary

Mathilde MERCKX FRATY, MD

Role: primary

Ana DIAZ CIVES, MD

Role: primary

Didier QUILLIOT, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PREPS-21-0030

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2023-A01309-36

Identifier Type: OTHER

Identifier Source: secondary_id

23.02108.000240

Identifier Type: OTHER

Identifier Source: secondary_id

APHP220835

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.